Evaluation of Pharmacokinetics of Simvastatin and Its Pharmacologically Active Metabolite from Controlled-Release Tablets of Simvastatin in Rodent and Canine Animal Models |
Shanmugam, Srinivasan
(Pharm. R&D Institute, Hanmi Pharm. Co., Ltd.)
Ryu, Jae-Kuk (Pharm. R&D Institute, Hanmi Pharm. Co., Ltd.) Yoo, Sun-Dong (College of Pharmacy, Sungkyunkwan University) Choi, Han-Gon (College of Pharmacy, Hanyang University) Woo, Jong-Soo (Pharm. R&D Institute, Hanmi Pharm. Co., Ltd.) |
1 | Prueksaritanont, T., Qiu, Y., Mu, L., Michel, K., Brunner, J., Richards, K. M. and Lin, J. H. (2005) Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfi brozil. Pharm. Res. 22, 1101-1109. DOI |
2 | Shu, X. Z., Zhu, K. J. and Song, W. (2001) Novel pH sensitive citrate crosslinked chitosan fi lm for drug controlled release. Int. J. Pharm. 212, 19-28. DOI |
3 | Singh, R. P., Gupta, R. C. and Singh, S. K. (2010) Interspecies comparison of the pharmacokinetics and oral bioavailability of 99-357, a potent synthetic trioxane antimalarial compound. Eur. J. Pharm. Sci. 41, 312-319. DOI |
4 | Sun, J. X., Niecestro, R., Phillips, G., Shen, J., Lukacsko, P. and Friedhoff, L. (2002) Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans. J. Clin. Pharmacol. 42, 198-204. DOI |
5 | Thielemann, A. M., Manquez, N., Pinilla, E., Gai, M. N., Romero, P., Arancibia, A. and Chavez, H. (1996) Chronopharmacokinetics of theophylline administered as a controlled-release tablet. Int. J. Clin. Pharmaco Ther. 34, 130-133. |
6 | Tobert, J. A. (1987) New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 76, 534-538. DOI ScienceOn |
7 | Vickers, S., Duncan, C. A., Chen, I. W., Rosegay, A. and Duggan, D. E. (1990a) Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab. Dispos. 18, 138-145. |
8 | Vickers, S., Duncan, C. A., Vyas, K. P., Kari, P. H., Arison, B., Prakash, S. R., Ramjit, H. G., Pitzenberger, S. M., Stokker, G. and Duggan, D. E. (1990b) In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos. 18, 476-483. |
9 | Pedersen, T. R. and Tobert, J. A. (2004) Simvastatin: a review. Expert Opin. Pharmacother. 5, 2583-2596. DOI |
10 | Davidson, M. H., Lukacsko, P., Sun, J. X., Phillips, G., Walters, E., Sterman, A., Niecestro, R. and Friedhoff, L. (2002) A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clin. Ther. 24, 112-125. DOI |
11 | Duggan, D. E., Chen, I. W., Bayne, W. F., Halpin, R. A., Duncan, C. A., Schwartz, M. S., Stubbs, R. J. and Vickers, S. (1989) The physiological disposition of lovastatin. Drug Metab. Dispos. 17, 166-173. |
12 | Duggan, D. E. and Vickers, S. (1990) Physiological disposition of HMGCoA-reductase inhibitors. Drug Metab. Rev. 22, 333-362. DOI |
13 | Goldbeter, A. and Claude, D. (2002) Time-patterned drug administration: insights from a modeling approach. Chronobiol. Int. 19, 157-175. DOI |
14 | Gotto, A. M. Jr. (1997) Results of recent large cholesterol-lowering trials and indications for clinical management. Am. J. Cardiol. 79, 1663-1666. DOI |
15 | Grundy, S. M. (1998) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 319, 24-33. |
16 | Halsas, M., Hietala, J., Veski, P., Jurjenson, H. and Marvola, M. (1999) Morning versus evening dosing of ibuprofen using conventional and timecontrolled release formulations. Int. J. Pharm. 189, 179-185. DOI |
17 | Hebert, P. R., Gaziano, J. M., Chanm K. S. and Hennekens, C. H. (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 278, 313-321. DOI |
18 | Higaki, K., Yamashita, S. and Amidon, G. L. (2001) Time-dependent oral absorption models. J. Pharmacokinet. Pharmacodyn. 28, 109-128. |
19 | Wikstrand, J., Andersson, B., Kendall, M. J., Stanbrook, H. and Klibaner, M. (2003) Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure. J. Cardiovasc. Pharmacol. 41, 151-157. DOI |
20 | Alberts, A. W. (1988) Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol. 62, 10J-15J. DOI |
21 | Lamson, M., Phillips, G., Shen, J., Lukacsko, P., Friedhoff, L. and Niecestro, R. M. (2002) Pharmacokinetics of lovastatin extendedrelease dosage form (Lovastatin XL) in healthy volunteers. Biopharm. Drug Dispos. 23, 143-149. DOI |
22 | Le Couteur, D. G., Martin, P. T., Bracs, P., Black, A., Hayes, R., Woolf, T. and Stern, R. (1996) Metabolism and excretion of [14C]-atorvastatin in patients with T-tube drainage. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol. 3, 153-158. |
23 | Lobenberg, R., Kim, J. S. and Amidon, G. L. (2005) Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. Eur. J. Pharm. Biopharm. 60, 17-23. DOI |
24 | Lukacsko, E. J., Walters, E. I., Cullen, R., Niecestro, L. and Friedhoff, T. (2004) Effi cacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia. Curr. Med. Res. Opinion. 20, 13-18. DOI |
25 | Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J. and Lenz, E. (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Ther. 25, 2822-2835. DOI |
26 | McClelland, G. A., Stubbs, R. J., Fix, J. A., Pogany, S. A. and Zentner, G. M. (1991) Enhancement HMG-CoA reductase inhibitor effi cacy through administration of a controlled-porosity osmotic pump dosage form. Pharm. Res. 8, 873-876. DOI |
27 | Nishio, S., Watanabe, H., Kosuge, K., Uchida, S., Hayashi, H. and Ohashi, K. (2005) Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens. Res. 28, 223-227. DOI |
28 | Alberts, A. W., Chen, J., Kuron, G., Hunt, V., Huff, J., Hoffman, C., Rothrock, J., Lopez, M., Joshua, H., Harris, E., Patchett, A., Monaghan, R., Currie, S., Stapley, E., Albers-Schonberg, G., Hensens, O., Hirshfi eld, J., Hoogsteen, K., Liesch, J. and Springer, J. (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterollowering agent. Proc. Natl. Acad. Sci. U.S.A. 77, 3957-3961. DOI |
29 | Kostner, G. M., Gavish, D., Leopold, B., Bolzano, K., Weintraub, M. S. and Breslow, J. L. (1989) HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a)levels. Circulation. 80, 1313-1319. DOI ScienceOn |
30 | Alberts, A. W. (1990) Effects of HMG CoA reductase inhibitors on cholesterol synthesis. Drug Invest. 2, 9-17. |
31 | Black, A. E., Hayes, R. N., Roth, B. D., Woo, P. and Woolf, T. F. (1999). Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab. Dispos. 27, 916-923. |
32 | Bradford, R. H., Shear, C. L., Chremos, A. N., Dujovne, C., Downton, M., Franklin, F. A., Gould, A. L., Hesney, M., Higgins, J., Hurley, D. P., Langendorfer, A., Nash, D. T., Pool, J. L. and Schnaper, H. (1991) Expanded clinical evaluation of lovastatin (EXCEL) study results: I. Effi cacy in modifying plasma lipoproteins and adverse event profi le in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med. 151, 43-49. DOI |
33 | Carroll, J. D., Reidy, M., Savundra, P. A., Cleave, N. and McAinsh, J. (1990) Longacting propranolol in the prophylaxis of migraine: a comparative study of two doses. Cephalalgia 10, 101-105. DOI |
34 | Cheng, H., Sutton, S. C., Pipkin, J. D., Zentner, G. M., Rogers, J. D., Schwartz, J. I., Mitchel, Y. B., Grasing, K., Schwartz, M. S., Amin, R. D., Liu, L., Ebel, D. L., Coulter, A., Engle, K., McClelland, G. A., Lui, C. Y. and Rork, G. S. (1993) Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors in dogs and humans. Pharm. Res. 10, 1683-1687. DOI |
35 | Woo, J. S., Yi, H. G., Chi, M. H., Ryu, J. K., Jung, S. Y. and Kim, Y. I. (2005) Sustained release formulation for oral administration of HMG-COA reductase inhibitor and method for the preparation thereof, PCT WO 2005097194. |
36 | Curran, M. P. and Goa, K. L. (2003) Lovastatin extended release: A review of its use in the management of hypercholesterolaemia. Drugs 63, 685-699. DOI |